About Esperion Therapeutics, Inc.
https://www.esperion.comEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
CEO
Sheldon L. Koenig
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 81
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Citizens Capital Markets
Market Outperform
JMP Securities
Market Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:14.83M
Value:$47.91M
BLACKROCK INC.
Shares:13.98M
Value:$45.17M
VANGUARD GROUP INC
Shares:12.09M
Value:$39.06M
Summary
Showing Top 3 of 248
About Esperion Therapeutics, Inc.
https://www.esperion.comEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $87.31M ▲ | $41.85M ▼ | $-31.33M ▼ | -35.89% ▼ | $-0.16 ▼ | $-9.26M ▼ |
| Q2-2025 | $82.39M ▲ | $46.75M ▼ | $-12.72M ▲ | -15.45% ▲ | $-0.02 ▲ | $7.79M ▲ |
| Q1-2025 | $65M ▼ | $55.55M ▲ | $-40.45M ▼ | -62.24% ▼ | $-0.21 ▼ | $-21M ▼ |
| Q4-2024 | $69.11M ▲ | $47.9M ▼ | $-21.32M ▲ | -30.85% ▲ | $-0.11 ▲ | $-4.87M ▲ |
| Q3-2024 | $51.63M | $50.37M | $-29.52M | -57.18% | $-0.15 | $-14.42M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $92.45M ▲ | $364.02M ▲ | $815.38M ▲ | $-451.36M ▼ |
| Q2-2025 | $86.06M ▼ | $347.08M ▲ | $780.59M ▲ | $-433.51M ▼ |
| Q1-2025 | $114.63M ▼ | $324.03M ▼ | $750.24M ▲ | $-426.21M ▼ |
| Q4-2024 | $144.76M ▲ | $343.82M ▲ | $732.54M ▲ | $-388.72M ▼ |
| Q3-2024 | $144.72M | $314.11M | $684.32M | $-370.21M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-31.33M ▼ | $-4.29M ▲ | $0 | $10.67M ▲ | $6.39M ▲ | $-4.29M ▲ |
| Q2-2025 | $-12.72M ▲ | $-31.42M ▼ | $0 | $2.85M ▲ | $-28.57M ▲ | $-31.42M ▼ |
| Q1-2025 | $-40.45M ▼ | $-22.63M ▲ | $0 | $-7.5M ▼ | $-30.13M ▼ | $-22.63M ▲ |
| Q4-2024 | $-21.32M ▲ | $-34.95M ▲ | $0 ▲ | $35M ▲ | $44K ▲ | $-34.95M ▲ |
| Q3-2024 | $-29.52M | $-35.33M | $-167K | $-9.1M | $-44.59M | $-35.49M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $80.00M ▲ | $30.00M ▼ | $40.00M ▲ | $50.00M ▲ |
 Product | $60.00M ▲ | $30.00M ▼ | $40.00M ▲ | $40.00M ▲ |
CEO
Sheldon L. Koenig
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 81
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Citizens Capital Markets
Market Outperform
JMP Securities
Market Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:14.83M
Value:$47.91M
BLACKROCK INC.
Shares:13.98M
Value:$45.17M
VANGUARD GROUP INC
Shares:12.09M
Value:$39.06M
Summary
Showing Top 3 of 248